The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis

Hui Liu1, Xiao-Li Yang2, Xiao-Yun Yang3, Zhao-Ru Dong1, Zhi-Qiang Chen1, Jian-Guo Hong1 and Tao Li1,4*

1 Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China, 2 Department of Nephrology, Jinan Central Hospital, Shandong University, Jinan, China, 3 Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan, China, 4 Department of Hepatobiliary Surgery, The Second Hospital of Shandong University, Jinan, China

Background: The lung immune prognostic index (LIPI) is recently developed to predict immune checkpoint inhibitors (ICIs) treatment outcomes for non-small cell lung cancer. However, its predictive value for other types of cancer remained unclear. This meta-analysis aimed to evaluate the association between pretreatment LIPI score and therapeutic outcomes in cancer patients treated with ICIs.

Methods: We searched PubMed, Cochrane Library literature databases and EMBASE for abstracts and full-text articles published from the inception of the database until 16th, Nov 2020. Meta-analyses were performed separately for progression-free survival (PFS) and overall survival (OS) by using the random-effects model.

Results: A total of 12 studies involving 4883 patients receiving ICIs treatment were identified for the primary analysis. The pooled results implied that compared with good LIPI score groups, patients with poor or intermediate LIPI score were significantly associated with worse OS (HR=3.33, 95%CI 2.64-4.21, P < 0.001, I² = 64.2%; HR=1.71, 95%CI 1.43-2.04, P < 0.001, I² = 43.6%, respectively) and PFS (HR=2.73,95%CI 2.00-3.73, P < 0.001, I² = 78.2%; HR=1.43, 95%CI 1.28-1.61, P < 0.001, I² = 16.3%, respectively). Also, for 1873 patients receiving chemotherapy, a poor LIPI score was significantly associated with worse OS (HR=2.30, 95%CI 1.73-3.07, P < 0.001; I² = 56.2%) and PFS (HR=1.92,95%CI 1.69-2.17; P < 0.001; I² = 0.0%) compared with good LIPI score groups.

Conclusions: A good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the types of cancer.

Keywords: lung immune prognostic index, immune checkpoint inhibitors, solid cancer, chemotherapy, meta-analysis
INTRODUCTION

Immune checkpoint inhibitors (ICIs) mainly include antibodies against cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1), and its major ligand (PD-L1) (1). ICIs have marked efficacy in the treatment of patients with solid cancers (2–4), still the majority of patients show intrinsic resistance to ICIs treatment owing to the tumor microenvironment (TME) and an impaired T cell tumor interaction mediated by immune escape mechanisms of tumor and immune cells (5). Therefore, resistance to ICIs treatment restricts patients with advanced cancer to achieve durable responses.

There are no candidate biomarkers for predicting response or resistance to immunotherapy in solid cancers, including hepatocellular carcinoma (6). Biomarkers that can predict whether patients have long-term favorable respond to ICIs therapy are eagerly awaited. At present, several biomarkers have been recognized to be associated with clinical outcomes for ICIs treatment. PD-L1, PD-1, neutrophil-lymphocyte ratio (NLR), tumor-infiltrating lymphocyte (TIL), microsatellite instability (MSI), gene expression profiling (GEP), and tumor mutational burden (TMB) can improve the predictive accuracy for ICIs outcomes in solid cancers (7–10).

The lung immune prognostic index (LIPI) was developed on the basis of derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) greater than three and lactate dehydrogenase (LDH) greater than upper limit of normal (ULN), characterizing three groups (good LIPI score group, 0 factor; intermediate LIPI score group, 1 factor; poor LIPI score group, 2 factors) (11). Current evidence proved that the LIPI score could be used to identify cancer patients who benefit from ICIs treatment in multiple cancers (11, 12). Meanwhile, contradictory results have also been published (13, 14).

Herein, we performed a systematic review and meta-analysis, to investigate the significance of the LIPI score as a predictive tool in solid cancer patients receiving ICIs treatment based on 12 published studies.

METHODS

This meta-analysis was performed by the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (15), with inclusion criteria being set out according to the PICOS model.

Search Methods and Study Selection Criteria

Two authors (HL, XLY) independently searched relevant studies from the PubMed, EMBASE, and Cochrane Library literature databases from the inception of the database until 16th, Nov 2020.

Those studies were restricted to the English language. The following search retrieval keywords for the literature were employed, including neoplasms, cancer, lung immune prognostic index, LIPI, PD-1, PD-L1, CTLA-4, nivolumab, atezolizumab, avelumab, durvalumab, ipilimumab, tremelimumab, pembrolizumab, ICIs, immune checkpoint inhibitor. The detailed search strategy is presented in Supplementary Retrieval Methods.

Two investigators (HL and XYY) independently screened the literature, and discrepancies were reviewed by another investigator on the team (TL) and resolved by consensus. The main criteria used for the eligibility study were as follows: (1) the studies in which patients were histologically diagnosed with cancer and treated with ICIs or chemotherapy. (2) the studies where the association between LIPI and therapeutic outcomes such as progression-free survival (PFS), overall survival (OS) were evaluated. (3) the studies where the related data could be collected directly or calculated indirectly. (4) the studies provided sufficient information to assess hazard ratio (HR) with 95% confidence interval (95%CI). (5) the studies that were published in English. For re-published research, only the latest literature and relevant data can be collected, or the research with the largest sample size can be selected.

Statistical Analysis

Data analyses were performed through Stata 12.0 statistical software (Stata Corp LP, College Station, TX). P < 0.05 was considered statistically significant. OS and PFS were used to evaluate the correlation between LIPI score and clinical data of cancer patients receiving ICIs or chemotherapy. HR with 95% CI was used for the pooled analyses of OS and PFS.

We compared the good LIPI score groups with the poor LIPI score, and intermediate LIPI score groups. Intermediate/poor (intermediate + poor) LIPI score groups were also compared with good LIPI score groups due to the combination of intermediate and poor LIPI score groups. Subgroup analyses were performed by cancer type, sample size, study region. At the same time, we also evaluated the association between different LIPI score and cancer patients receiving chemotherapy. Meta-analysis was used to pool the estimates, using the random-effects model.

Statistical heterogeneity was evaluated by using the Cochran Q and the inconsistency index (I²) statistic tests. P > 0.05 and I² <
50% indicated a lack of heterogeneity among all studies. We chose the random effect model in this meta-analysis due to the inherent clinical heterogeneity among studies included in this meta-analysis (17). Funnel plots, Egger’s regression asymmetry test, and Begg’s rank correlation test were used to examine the potential publication bias (18).

RESULTS

Retrieval Result and Study Characteristics
A flow chart of the literature search process is summarized in Figure 1. In total, 76 records were initially identified. Then, 45 studies were retained after the removal of duplicates. After screening for titles and abstracts, 6 records were excluded (not relevant, review, not ICIs or chemotherapy). After reviewing the remaining 39 articles via the full-text view, 27 full-text articles were excluded due to lack of intended outcomes (OS, PFS), HR with 95% CI or repeatedly published studies. Finally, 12 studies published between 2018 and 2020 were included in this analysis (11–14, 19–26).

The detailed characteristics of all eligible studies are presented in Table 1. One of twelve studies was prospectively designed; the rest of the literature was retrospectively designed. In total, our meta-analysis included 4883 cancer patients receiving ICIs treatment. The sample size was ranging from 70 to 1489 per study. Eight studies were conducted in Europe; two were conducted in China; one was from Australia; one was conducted in Canada; a conference abstract was not reported. Among these studies, seven studies included patients with non-small cell lung cancer (NSCLC), one for hepatocellular carcinoma and one with squamous cell carcinoma of the head and neck (SCCHN); the rest four studies for other types or multiple cancers. All patients enrolled were treated with ICIs or chemotherapy. The quality assessment results of the all 12 studies ranged from 5 to 7, as shown in Table 1. Four studies scored 7 points, seven studies scored 6 points, and one study scored 5 points.

Association Between LIPI Score and OS or PFS of Cancer Patients Receiving ICIs Treatment
OS data was available in 8 studies involving 4443 patients receiving ICIs treatment. Compared with good LIPI score groups, poor LIPI score groups were significantly associated with worse OS (HR=3.33, 95%CI =2.64-4.21; P< 0.001), with a significant level of heterogeneity (I² = 64.2%, P=0.003) among the studies (Figure 2). Intermediate LIPI score predicted poor OS compared with good LIPI score groups (HR=1.717, 95%CI 1.43-2.04; P< 0.001) (Figure 2) with a moderate level of heterogeneity (I² = 43.6%, P=0.088). The sensitivity analysis
showed that the pooled OS results (Supplementary Figures 1 and 2) were not significantly changed by any single study.

PFS data was available in 4 studies involving 3669 patients. The pooled results implied that poor LIPI score groups had a significantly higher risk of poor PFS compared with good LIPI score groups (HR = 2.73, 95%CI 2.00-3.73, P < 0.001). The heterogeneity test showed significant heterogeneity existed among these studies ($I^2 = 78.2\%, P< 0.001$) (Figure 3). The pooled results revealed that intermediate LIPI score indicated poor PFS compared with good LIPI score groups (HR=1.43, 95%CI 1.28-1.61, P< 0.001) with a moderate level of heterogeneity ($I^2 = 16.3\%$, P=0.309) (Figure 3).

4 studies, covering 440 patients receiving ICIs treatment, were analyzed separately due to the combination of intermediate and...
Association Between LIPI Score and OS or PFS of Cancer Patients Receiving Chemotherapy

3 of the 12 studies involving 1873 patients receiving chemotherapy provided OS and PFS data. According to the random-effects model, compared with the group with good LIPI score, the group with poor LIPI score was significantly correlated with the group with inferior OS (HR=2.30, 95%CI 1.73-3.07, P < 0.001) (Figure 5) and PFS (HR=1.92, 95%CI 1.69-2.17; P < 0.001) (Figure 6). The heterogeneity test showed that heterogeneity existed among these studies (I² = 56.2%, P=0.077), but not PFS (I² = 0.0%, P=0.592). Intermediate LIPI score was also a significant association with worse OS (HR=1.54, 95%CI 1.27-1.86, P < 0.001) (Figure 5) and PFS (HR=1.45, 95%CI 1.29-1.64; P < 0.001) (Figure 6) compared with good LIPI score groups. Neither of them is heterogeneous (I² = 0.0%, P=0.646; I² = 0.0%, P=0.639). However, the LIPI score may not predict therapeutic outcomes in cancer patients receiving chemo-immunotherapy (26). The sensitivity analysis also showed that no individual study influenced the pooled effects on OS and PFS (Supplementary Figures 6 and 7).

Association Between Subgroup Analyses and OS or PFS

Subgroup analyses for OS and PFS were further performed to assess the interaction of LIPI score with cancer type, sample size, and study region and the results are shown in Table 2. When stratifying by cancer type, compared with the good LIPI score groups, poor LIPI score was significantly associated with worse OS and PFS in patients with NSCLC (OS: HR=3.011, 95%CI 2.303-3.936; P<0.001) (PFS: HR=3.011, 95%CI 2.303-3.936; P<0.001) and multiple/other (OS: HR=4.107, 95%CI 2.525-6.0681; P<0.001) (PFS: HR=4.791, 95%CI 2.997-7.659; P<0.001) (Table 2). The conclusion was the same when stratifying by sample size and study region. There was significant heterogeneity in the sample size less than 200 (I² = 82.8%, P=0.001) and multiple/other (OS: HR=4.107, 95%CI 2.525-6.0681; P<0.001) (PFS: HR=4.791, 95%CI 2.997-7.659; P<0.001) (Table 2). The sensitivity analysis also showed that no individual research influenced the pooled effects on OS and PFS (Supplementary Figures 6 and 7).

Publication Bias

The funnel plot indicated no significant publication bias in all the pooled analyses (Supplementary Figures 8 and 9). Funnel plot
asymmetry was further assessed by the method of Egger’s and Begg’s linear regression test (P < 0.05 was considered a significant publication bias) (18). The Begg’s and Egger’s test also revealed no evidence of publication bias for OS (Begg’s test: P = 0.534, Egger’s test: P = 0.536) and PFS (Begg’s test: P = 0.707, Egger’s test P = 0.021) (Supplementary Figures 10 and 11). We did not conduct a publication bias analysis for those with too few studies.
DISCUSSION

The LIPI score is developed based on LDH and dNLR, which are simple and easy to calculate (11). In this meta-analysis, we have evaluated the association of LIPI score with the prognosis of cancer patients receiving ICIs or chemotherapy. Compared with good LIPI score groups, the pooled results show that regardless of whether the patients received ICIs or chemotherapy, the OS and PFS of the poor or intermediate LIPI score group were significantly reduced.

Although some studies have shown that the LIPI score cannot be used to identify cancer patients who have benefited from chemotherapy, these data are not available (11).

Inflammation plays a key role in tumor progression, affecting the survival of cancer patients (27). The inflammatory status of various

TABLE 2 | Subgroup analyses of the associations between LIPI score and outcomes (poor vs. good).

| Subgroup                | Number of studies | Pooled results | Heterogeneity test | Publication Bias test |
|-------------------------|-------------------|----------------|-------------------|----------------------|
|                         |                   | HR (95% CI) %  |                  |                      |
|                         |                   | P              | I2                | P (Begg’s) | P (Egger’s) |
| Overall survival        |                   |                |                  |                      |
| All studies             | 10                | 3.332 (2.639-4.208) | <0.001           | 64.2       | 0.003       | 0.859       | 0.939       |
| Cancer type             |                   |                |                  |                      |
| NSCLC                   | 5                 | 3.011 (2.303-3.936) | <0.001           | 70.8       | 0.008       | 0.462       | 0.376       |
| Multiple/other          | 5                 | 4.107 (2.525-6.068) | <0.001           | 58.5       | 0.047       | 1           | 0.75        |
| Sample size             |                   |                |                  |                      |
| <200                    | 4                 | 3.571 (1.547-8.244) | 0.003           | 82.8       | 0.001       | 0.734       | 0.388       |
| >200                    | 6                 | 3.416 (2.892-4.038) | <0.001           | 29.2       | 0.216       | 0.858       | 0.939       |
| Study region            |                   |                |                  |                      |
| Canada                  | 3                 | 4.659 (2.996-7.496) | <0.001           | 48.9       | 0.141       | 1           | 0.874       |
| Europe                  | 5                 | 3.001 (2.301-3.914) | <0.001           | 33.6       | 0.198       | 1           | 0.747       |
| Others                  | 2                 | 2.669 (1.174-6.069) | 0.019           | 89.4       | 0.002       | 1           | 0.219       |
| Progression-free survival|                  |                |                  |                      |
| All studies             | 6                 | 2.733 (2.000-3.733) | <0.001           | 78.2       | <0.001      | 0.707       | 0.021       |
| Cancer type             |                   |                |                  |                      |
| NSCLC                   | 4                 | 2.242 (1.717-2.929) | <0.001           | 70.9       | 0.016       | 0.734       | 0.182       |
| Multiple/other          | 2                 | 4.791 (2.997-7.659) | <0.001           | 0.0        | 0.427       | 1           | 0.219       |
| Sample size             |                   |                |                  |                      |
| <200                    | 2                 | 4.492 (2.867-7.039) | <0.001           | 4.9        | 0.305       | 1           | 0.219       |
| >200                    | 4                 | 2.232 (1.704-2.922) | <0.001           | 70.3       | 0.018       | 0.737       | 0.198       |
| Study region            |                   |                |                  |                      |
| Canada                  | 3                 | 3.760 (2.562-5.520) | <0.001           | 33.1       | 0.224       | 1           | 0.481       |
| Others                  | 2                 | 2.464 (1.476-4.114) | <0.001           | 62.9       | 0.1         | 1           | 0.219       |

LIPI, lung immune prognostic index; NSCLC, non-small cell lung cancer; HR, hazard ratio.
cancers can be measured by dNLR. As an essential component of the inflammatory response, neutrophils not only target tumor cells, but also indirectly act on the tumor microenvironment to promote tumor development (28). Lymphocyte infiltration in the tumor is also associated with a better response to immunotherapy and prognosis in solid tumor patients (29). LDH and dNLR are independent risk factors for mortality among patients, and are correlated with poor outcomes in several solid cancer types according to the current evidence (30, 31).

Immunotherapy has demonstrated great clinical success in certain cancers, but so far, immunotherapy has only achieved success in a limited number of cancers (32). Specifically, Callahan, M.K., et al. have demonstrated that the majority of such patients can now be successfully treated with concurrent ipilimumab and nivolumab therapy (33). However, the deleterious effects of immune-related adverse events (irAEs) might outweigh the benefit from the addition of ipilimumab (34). Until now, there is still no biomarker for some cancers to predict the response or resistance to immunotherapy (6). Robust biomarkers are needed to predict patient responsiveness to immunotherapy and for their stratification (35). Our meta-analysis provides new evidence supporting that LIPI scores are used as prognostic indicators for cancer patients receiving ICIs or chemotherapy. In addition, LIPI score may also has prognostic value for doublet immunotherapy such as ipilimumab and nivolumab, as one included study has revealed the potential application of the LIPI scores in such circumstances (12). However, more studies are warranted to fully exploit its predictive value.

Our findings suggest that the LIPI scores may be a promising predictive biomarker for the therapeutic outcomes of ICIs or chemotherapy in solid cancer patients. The pooled results for subgroup analyses, which involved types of cancer, sample size, and study regions, indicated that there is significant heterogeneity in the sample size less than 200, and other study regions (including Australia and China). Previously, the LIPI score may be an independent and complemented indicator for improved survival in cancer patients receiving immunotherapy or chemotherapy, because there was no significant correlation among PD-L1, TMB, and LIPI score (36).

Although our analysis provided a comprehensive summary of current literature, our present study still had some limitations that need to be considered. First of all, the major limitation lies in the fact that most of the included studies were retrospective, leading to some unavoidable bias sources. Secondly, only studies published in English were included, which may lead to publication bias. Cancer type is also a limitation; thus, we performed a subgroup analysis to further explain the correlation between LIPI score and the clinicopathologic features of patients receiving ICIs or chemotherapy. Although there is significant heterogeneity when the sample size is less than 200, this does not affect our results. Further high-quality prospective study is warranted.

CONCLUSIONS

In summary, a good LIPI score was significantly correlated with improved OS and PFS in cancer patients receiving ICIs or chemotherapy, regardless of the different types of cancer. Our analysis supported that the LIPI score is a reliable predictive tool that can be used to identify cancer patients who benefit from ICIs or chemotherapy, and to guide decisions in the era of personalized cancer treatments.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

HL and TL designed the study. HL, X-LY, and Z-RD performed the systematic search. HL, X-LY, X-YY, Z-RD, and Z-QC selected eligible articles and conducted the quality assessment. HL and X-LY analyzed, interpreted the data, and drafted the manuscript. TL revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the grants from the Taishan Scholars Program for Young Expert of Shandong Province (Grant No. tsqn20161064), National Natural Science Foundation of China (Grant No. 82073200 & 81874178), and founds for Independent Cultivation of Innovative Team from Universities in Jinan (Grant No. 2020GXRC023).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.691002/full#supplementary-material

REFERENCES

1. Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV Induced Hepatocellular Carcinoma and Related Potential Immunotherapy. Pharmacol Res (2020) 159:104992. doi: 10.1016/j.phrs.2020.104992.
2. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J Clin Oncol Off J Am Soc Clin Oncol (2010) 28 (19):3167–75. doi: 10.1200/jco.2009.26.7609.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New Engl J Med (2012) 366(26):2443–54. doi: 10.1056/NEJMoa1200690.
4. Wang D, Hao H, Li X, Wang Z. The Effect of Intestinal Flora on Immune Checkpoint Inhibitors in Tumor Treatment: A Narrative Review. Ann Trans Med (2020) 8(17):1097. doi: 10.21037/atm-20-4535.
5. Seliger B. The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment-Review. Front Immunol (2019) 10:2043. doi: 10.3389/fimmu.2019.02043

6. Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for Advanced Hepatocellular Carcinoma: A Focus on Special Subgroups. Gut (2020) 70 (1):204–14. doi: 10.1136/gutjnl-2020-321702

7. Sha D, Jin Z, Budczies J, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery (2020). doi: 10.1158/2159-8290.cd-20-0522

8. Huang Y, Shen A. The Prediction Potential of Neutrophil-to-Lymphocyte Ratio for the Therapeutic Outcomes of Programmed Death Receptor-1/Programmed Death Ligand 1 Inhibitors in non-Small Cell Lung Cancer Patients: A Meta-Analysis. Medicine (2020) 99(4):e21718. doi: 10.1097/md.0000000000002178

9. Chen H, Wang D, Zhong Q, Tao Y, Zhou Y, Shi Y. Pretreatment Body Mass Index and Clinical Outcomes in Cancer Patients Following Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancer Immunol Immunother CII (2020). doi: 10.1007/s00262-020-02680-y

10. Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-Analysis. JAMA Oncol (2019) 5 (8):1195–204. doi: 10.1001/jamaoncol.2019.1549

11. Mezquita L, Ausin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol (2018) 4(3):351–7. doi: 10.1001/jamaoncol.2017.4777

12. Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, et al. The Head and Neck Lung Immune Prognostic Index (HN-LIPI): A Prognostic Score for Immune Checkpoint Inhibitors (ICD) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCN) Patients. Ann Oncol (2019) 30:v649–70. doi: 10.1093/annonc/mdz252.051

13. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration. BMJ (Clin Res Ed) (2009) 339:b2700. doi: 10.1136/bmj.b2700

14. Sanz A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. Eur J Epidemiol (2010) 25(9):603–5. doi: 10.1007/s10654-009-9491-6

15. DerSimonian R, Laird N. Meta-Analysis in Clinical Trials. Controlled Clin Trials (1986) 7(3):177–88. doi: 10.1016/0197-2456(86)90046-2

16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in Meta-Analysis Detected by a Simple, Graphical Test. BMJ (Clin Res Ed) (1997) 315(7109):629–34. doi: 10.1136/bmj.315.7109.629

17. Al Darazi G, Martin E, Delord JP, Korakis I, Betrian S, Poublanc M, et al. Improving Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-Small Cell Lung Cancer. Front Oncol (2020) 10:572853. doi: 10.3389/fonc.2020.572853

18. Liu Y, Zhang H, Yu Y, Yan X, Song Q, Wang G, et al. Pretreatment Neutrophil-To-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol (2020) 10:6654. doi: 10.3389/fonc.2020.06654

19. Templeton AI, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J Natl Cancer Inst (2014) 106(6): dju124. doi: 10.1093/jnci/dju124

20. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The Prognostic Influence of Tumour-Inf inflating Lymphocytes in Cancer: A Systematic Review With Meta-Analysis. Br J Cancer (2011) 105(1):93–103. doi: 10.1038/bjc.2011.189

21. Takada K, Takamori S, Matsubara T, Haratake N, Akamine T, Kinoshita F, et al. Clinical Significance of Preoperative Immunomarker in non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Study. PloS One (2020) 15(11):e0241580. doi: 10.1371/journal.pone.0241580

22. Liu C, Li L, Song K, Zhang ZY, Yao Y, Gong H, et al. A Nomogram for Predicting Mortality in Patients With COVID-19 and Solid Tumors: A Multicenter Retrospective Cohort Study. J Immunother Cancer (2020) 8(2). doi: 10.1136/jitc-2020-001314

23. Jiao W, Zhang J, Li Y, Liu X, Cao Y, Wang S, et al. Incidence Rates of Immune-Related Adverse Events and Their Correlation With Response in Advanced Solid Tumors Treated With NIVO or NIVO+IPE: A Systematic Review and Meta-Analysis. J Immunother Cancer (2019) 7(1):341. doi: 10.1186/s40425-019-0779-6

24. Santa Gadea OS, Hernando-Calvo A, Berchê R, Matos I, Gardeazabal I, Pedrazzoli ABA, et al. Limited Efficacy of Immunotherapy Combination Regimens in Patients With Unselected “Cold” Tumours Enrolled in Early Clinical Trials. Ann Oncol (2020) 31:S489. doi: 10.1016/annonc.2020.08.868

25. Sorich MJ, Rowland A, Karapetis CS, Hopkins AM. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2019) 14(6):1440–6. doi: 10.1016/j.jtho.2019.04.006

26. Wang W, Huang Z, Yu Z, Zhuang W, Zheng W, Cai Z, et al. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-Small Cell Lung Cancer. Front Oncol (2020) 10:572853. doi: 10.3389/fonc.2020.572853

27. Liu Y, Zhang H, Yu Y, Yan X, Song Q, Wang G, et al. Pretreatment Neutrophil-To-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol (2020) 10:6654. doi: 10.3389/fonc.2020.06654

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Liu, Yang, Yang, Dong, Chen, Hong and Li. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.